The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma.

@article{Baker2006TheAT,
  title={The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma.},
  author={Amanda F Baker and Tomislav Dragovich and Wendy R Tate and Ramesh K. Ramanathan and Denise Roe and Chiu-Hsieh Hsu and D. Lynn Kirkpatrick and Garth Powis},
  journal={The Journal of laboratory and clinical medicine},
  year={2006},
  volume={147 2},
  pages={83-90}
}
Thioredoxin-1 (Trx-1) is a small redox protein that is overexpressed in many human tumors, where it is associated with aggressive tumor growth and decreased patient survival. Trx-1 is secreted by tumor cells and is present at increased levels in the plasma of cancer patients. PX-12 is an irreversible inhibitor of Trx-1 currently in clinical development as an antitumor agent. We have used SELDI-TOF mass spectroscopy to measure plasma Trx-1 from patients treated with PX-12 during a phase I study… CONTINUE READING
27 Extracted Citations
46 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 27 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 46 references

Similar Papers

Loading similar papers…